RT Journal Article
SR Electronic
T1 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.17.21262196
DO 10.1101/2021.08.17.21262196
A1 McGree, J. M.
A1 Hockham, C.
A1 Kotwal, S.
A1 Wilcox, A.
A1 Bassi, A.
A1 Pollock, C.
A1 Burrell, L. M.
A1 Snelling, T.
A1 Jha, V.
A1 Jardine, M.
A1 Jones, M.
A1 for the CLARITY Trial Steering Committee
YR 2021
UL http://medrxiv.org/content/early/2021/08/22/2021.08.17.21262196.abstract
AB The CLARITY trial (Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease) investigates the effectiveness of angiotensin receptor blockers in addition to standard care compared to placebo (in Indian sites) with standard care in reducing the duration and severity of lung failure in patients with COVID-19. The CLARITY trial is a multi-centre, randomised controlled Bayesian adaptive trial with regular planned analyses where pre-specified decision rules will be assessed to determine whether the trial should be stopped due to sufficient evidence of treatment effectiveness or futility. Here we describe the statistical analysis plan for the trial, and define the pre-specified decision rules, including those that could lead to the trial being halted. The primary outcome is clinical status on a 7-point ordinal scale adapted from the WHO Clinical Progression scale assessed at Day 14. The primary analysis will follow the intention-to-treat principle. A Bayesian adaptive trial design was selected because there is considerable uncertainty about the extent of potential benefit of this treatment.Trial registration ClinicalTrials.gov, NCT04394117. Registered on 19 May 2020.https://clinicaltrials.gov/ct2/show/NCT04394117Clinical Trial Registry of India: CTRI/2020/07/026831Version and revisions Version 1.0. No revisions.Competing Interest StatementJM, CH, SK, AW, AB, LB, NB, MK, VR, MJoh, EL, AR, AM, TS, MJon have no conflicts of interest to disclose. CP serves on advisory boards for AstraZeneca, Boehringer Ingelheim, Merck Sharp and Dohme and Novartis. CJ serves on advisory boards for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Sanofi-Genzyme. VJ has received grants from Baxter Healthcare, Biocon and GlaxoSmithKline, and speaker fees/advisory board from AstraZeneca, Baxter Healthcare, NephroPlus, Sanofi - all outside the submitted work. All fees paid to the organization. MJar is responsible for research projects that have received unrestricted funding from Amgen, Baxter, Bayer, CSL Behring, Eli Lilly, Gambro, and Merck Sharp and Dohme; has served on advisory boards sponsored by Akebia, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Merck Sharp and Dohme and Vifor; serves on the Steering Committee for trials sponsored by Chinook, CSL Behring and Janssen; serves on a Steering Committee for an investigator initiated trial in COVID-19 disease with funding support from Dimerix; spoken at scientific meetings sponsored by Amgen, Janssen, Roche and Vifor; with any consultancy, honoraria or travel support paid to the institution.Clinical TrialNCT04394117Funding StatementCLARITY is supported by the Australian Government's Medical Research Future Fund Respiratory Medicine Clinical Trials Research on COVID-19 2020 grant scheme (ref. no. APP2002277).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sydney Local Health District Ethics Review CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are currently being collected as part of an active clinical trial.ARBsAngiotensin Receptor Blockers;AT1RAngiotensin II type 1 receptor;BERNBernoulli;CONSORTConsolidated Standards of Reporting Trials;CLARITYControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease;COVID-19Coronavirus disease 2019;DSMBData Safety Monitoring Board;ICUIntensive care unit;MARMissing at random;MCARMissing completely at random;MCMCMarkov chain Monte Carlo;MNARMissing not at random;RAASRenin-Angiotensin-Aldosterone System;RASRenin-angiotensin system;SAPStatistical analysis plan;SARS-CoV-2Severe acute respiratory syndrome coronavirus 2;SDStandard deviation;VFDsVentilator-free days